Drugs / rMenB+OMV NZ
last change Feb 2012 re-read 2 minutes ago

rMenB+OMV NZ

also known as 4CMenB

Vaccine

Developed for
meningococcal infection
Investigated by
Novartis Vaccines

Trials 1 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00721396 Aug 2008 → Jul 2010 meningococcal infection Novartis Vaccines Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as rMenB+OMV NZ ClinicalTrials.gov intervention name — accepted as the source's own label NCT00721396
Known as 4CMenB “To determine the immunogenicity and reactogenicity of a multicomponent MenB vaccine (4CMenB) and routine infant vaccines when given either concomitantly or separately.” PMID 22318278 Feb 2012
Modality Vaccine “rMenB+OMV NZ vaccine at 2, 4, and 6 months of age” NCT00721396